bioMérieux, a global leader in invitro diagnostics, unveils that it has reached an agreement to procure Specific Diagnostics, a privately held American Company that has created a rapid antimicrobial susceptibility test (AST) system that provides phenotypic AST directly from positive blood cultures.
A corporation among DiaSorin (FTSE MIB: DIA) and B.R.A.H.M.S. GmbH, a division of Thermo Fisher Scientific, has been formed with the goal of developing and marketing the novel LIAISON B.R.A.H.M.S MR-proADM immunodiagnostic test. The test can assist in the detection of several serious illnesses, including sepsis, septic shock, lower respiratory infections, urinary tract infections, and kidney disease.
Author Credits: Radhika Gupta, Shivam Bhutani